Ginkgo Bioworks Unit Zymergen to Liquidate After Selling Assets

Biotech firm Zymergen Inc., a subsidiary of Ginkgo Bioworks, won bankruptcy court approval of a liquidation plan after laying off employees and selling its assets.

• Judge Karen Owens said Monday she’d approve Zymergen’s Chapter 11 liquidation plan months after the firm filed for bankruptcy protection in October
• Zymergen, which merged with Ginkgo Bioworks in 2022, said at the time it filed for bankruptcy that although the firm believed it had extremely valuable assets the company continued to lose money
  • The firm developed products for agriculture, new-drug discovery, 3D printing, data science and genetics; the company terminated about 320 ...